Assessment of the immunogenicity and safety of the Northern Hemisphere 2008/2009-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulations
| ISRCTN | ISRCTN40098615 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN40098615 |
| Secondary identifying numbers | INF-V-A002 |
- Submission date
- 16/04/2008
- Registration date
- 22/05/2008
- Last edited
- 28/04/2009
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Michael Seiberling
Scientific
Scientific
Swiss Pharma Contract Ltd
Lettenweg 118
Allschwil
4123
Switzerland
Study information
| Study design | Open non-randomised uncontrolled safety/efficacy study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Other |
| Study setting(s) | Not specified |
| Study type | Prevention |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | |
| Study objectives | The Northern Hemisphere 2008/2009-season influenza vaccine fulfills the European Medicines Agency (EMEA) requirements for re-registration of influenza vaccines. |
| Ethics approval(s) | Ethics approval received from the Local Medical Ethics Committee (Ethikkommission beider Basel [EKBB]), Switzerland on the 28th February 2008 (ref: 57/08). |
| Health condition(s) or problem(s) studied | Influenza |
| Intervention | Biological: single dose of trivalent virosomal adjuvanted influenza vaccine (Inflexal® V). Total duration of follow-up: approximately three weeks. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Trivalent virosomal adjuvanted influenza vaccine (Inflexal® V) |
| Primary outcome measure | Immunogenicity, assessed by haemagglutination inhibition test; blood to be collected before and approximately three weeks after vaccination. |
| Secondary outcome measures | Safety, assessed at baseline and at three weeks after vaccination, including a four-day adverse event questionnaire, soliciting a set of local and systemic adverse events (AEs) according to the European Medicines Agency (EMEA) specifications. |
| Overall study start date | 01/06/2008 |
| Completion date | 30/08/2008 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 110 |
| Key inclusion criteria | 1. Healthy female and male volunteers equal to or older than 18 years of age 2. Written informed consent |
| Key exclusion criteria | 1. Pregnancy and lactation 2. Serious adverse reaction to any influenza vaccine |
| Date of first enrolment | 01/06/2008 |
| Date of final enrolment | 30/08/2008 |
Locations
Countries of recruitment
- Switzerland
Study participating centre
Swiss Pharma Contract Ltd
Allschwil
4123
Switzerland
4123
Switzerland
Sponsor information
Crucell, Berna Biotech Ltd (Switzerland)
Industry
Industry
Rehhagstrasse 79
Berne
3018
Switzerland
| info@crucell.com | |
| Website | http://www.crucell.com/ |
Funders
Funder type
Industry
Crucell, Berna Biotech Ltd (Switzerland)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
